The potential for drug interactions with DOACs in patients with atrial fibrillation (AF) has decreased slightly in recent years, but there is still room for improvement in the co-prescribing of DOACs and medications which may decrease their safety and efficacy. An Australian study interrogating the national GP dataset examined trends in the co-prescribing of DOACs ...
Co-prescribing study shows need to lower risk of drug interactions with DOACs
By Mardi Chapman
30 Nov 2020